Thompson A, Danesh J
Department of Public Health and Primary Care, University of Cambridge, Cambridge, UK.
J Intern Med. 2006 May;259(5):481-92. doi: 10.1111/j.1365-2796.2006.01644.x.
To assess associations of circulating levels of apolipoprotein (apo) AI, apoB and the apoB/AI ratio (apoB/A) with risk of incident coronary heart disease (CHD).
Literature-based meta-analysis of prospective studies.
Prospective studies in essentially general populations that reported on associations between apoAI, apoB or apoB/A and first incident CHD outcomes. Studies were identified by computer-based searches and by manual searches of the relevant literature.
Data from 23 relevant studies were identified. For apoAI, with 6333 CHD cases in 21 studies, comparison of individuals in the bottom third with those in the top third of baseline values yielded a combined relative risk of 1.62 (95% confidence interval: 1.43-1.83), i.e. an inverse association. For apoB, a combined analysis of 6320 CHD cases from 19 studies gave a relative risk of 1.99 (1.65-2.39) for a comparison of individuals in the top third versus those in the bottom third of baseline values. For apoB/A, with 3730 CHD cases from seven studies, a comparison of individuals in the top third versus the bottom third of baseline values gave a combined relative risk of 1.86 (1.55-2.22). These associations were somewhat stronger following correction for within-person variations in apolipoprotein levels. There was evidence of heterogeneity amongst the published studies, but it was only partly explained by available study-level characteristics.
The present quantitative review suggests the existence of moderately strong associations between baseline levels of each of apoAI, apoB, and apoB/A and risk of CHD. More detailed analysis, perhaps based on individual participant data from prospective studies, could help to overcome several limitations in the present review and to clarify any relevance of these apolipoproteins to disease prediction and aetiology.
评估载脂蛋白(apo)AI、apoB的循环水平以及apoB/AI比值(apoB/A)与冠心病(CHD)发病风险之间的关联。
基于文献的前瞻性研究荟萃分析。
主要针对普通人群的前瞻性研究,这些研究报告了apoAI、apoB或apoB/A与首次发生冠心病结局之间的关联。通过计算机检索和手动检索相关文献来识别研究。
确定了23项相关研究的数据。对于apoAI,在21项研究中的6333例冠心病病例中,将基线值处于最低三分之一的个体与最高三分之一的个体进行比较,得出综合相对风险为1.62(95%置信区间:1.43 - 1.83),即呈负相关。对于apoB,对19项研究中的6320例冠心病病例进行综合分析,将基线值处于最高三分之一的个体与最低三分之一的个体进行比较,得出相对风险为1.99(1.65 - 2.39)。对于apoB/A,在7项研究中的3730例冠心病病例中,将基线值处于最高三分之一的个体与最低三分之一的个体进行比较,得出综合相对风险为1.86(1.55 - 2.22)。在校正载脂蛋白水平的个体内变异后,这些关联稍强。已发表的研究之间存在异质性证据,但仅部分可由现有的研究水平特征解释。
本定量综述表明,apoAI、apoB和apoB/A的基线水平与冠心病风险之间存在中等强度的关联。更详细的分析,或许基于前瞻性研究的个体参与者数据,可能有助于克服本综述中的若干局限性,并阐明这些载脂蛋白与疾病预测和病因学的任何相关性。